BioAlliance Pharma Strengthens its Proprietary Technologies with the Grant of Its Lauriad(TM) Patents in Asia and With the Transfer of Setofilm(R) Back to APR Applied Pharma Research S.A., the Owner of the Technology

Published: Jun 10, 2011

Paris, June 10, 2011 – BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the grant of patents protecting its delivery technology Lauriad™ in China and Japan. This delivery technology specifically covers its advanced Specialty products: Loramyc® in the treatment of oropharyngeal candidiasis and Sitavir® in herpes labialis.

“After Europe and the US, these grants in Asia mark a new step in the international recognition of the innovation represented by the Lauriad™ mucoadhesive concept, with an early and prolonged release of the active ingredient at the site of infection”, commented Dominique Costantini, CEO of BioAlliance Pharma. “These grants strengthen our positioning on the oropharyngeal candidiasis market in China with Sciclone/Novamed and in Japan with Sosei, giving a competitive advantage to our partners who develop and will market our Loramyc® mucoadhesive tablet”, added Judith Greciet, COO of BioAlliance Pharma.

Intellectual property is a key asset of the Company. BioAlliance Pharma’s patent portfolio reflects the Company’s strategy and today consists of 30 families of published patents, including 340 patents and patent requests concerning innovative products or technologies. Nearly 70% of the patent portfolio provides protection for the Specialty and the Orphan oncology products.

BioAlliance Pharma and APR Applied Pharma Research SA have jointly decided to transfer back to APR the European commercialization rights of the specialty product Setofilm®. This decision, simplifying the organization, results from an in-depth analysis of the partners. Setofilm®, as a thin film strip of ondansetron, dissolves in few seconds in the mouth. BioAlliance has obtained in 2010 its marketing authorizations in 16 European countries for the treatment of –chemotherapy, radiotherapy and post operative-induced nausea and vomiting. BioAlliance will use its know-how to optimize the marketing authorizations of the product until APR sets up the most appropriate commercial organization.

“As for our specialty products, we have chosen to refocus on the proprietary technologies while leading an active in and out research to reinforce our orphan oncology products portfolio”, added Judith Greciet.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products –– BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU US, Korea)

Setofilm® (prevention and treatment of nausea and vomiting post chemo-radiotherapy and post operative) - Registered in EU

Sitavir® (Acyclovir Lauriad TM) (labialis herpes): Positive phase III final results; registration status

Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Phase II results on survival

Clonidine LauriadTM (mucositis): Phase II on going

AMEP® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website ( or on BioAlliance Pharma SA's website (

BioAlliance Pharma SA

Dominique Costantini, CEO

Tel.: +33 1 45 58 76 01

Judith Greciet, COO

Tel +33 1 45 58 70 61

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00


Caroline Carmagnol

Tel.: +33 6 64 18 99 59

Back to news